NASHVILLE, Tenn., March 18, 2026 (GLOBE NEWSWIRE) — Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that three scientific abstracts highlighting its commercial products
VEVYE
®
(cyclosporine ophthalmic solution) 0.1%
and
ILEVRO
®
(nepafenac ophthalmic suspension) 0.3%
have been accepted for presentation at the American Society of Cataract and Refractive Surgery (ASCRS) 2026 Annual Meeting, taking place April 10–13 at the Walter E. Washington Convention Center in Washington, D.C.